Review: Contrast-enhanced magnetic resonance in the diagnosis and management of cardiac sarcoidosis

J.P. Smedema; G. Ainslie; H.J.G.M. Crijns

doi:10.1016/j.pcad.2020.03.011

Review: Contrast-enhanced magnetic resonance in the diagnosis and management of cardiac sarcoidosis

J.P. Smedema^*, G. Ainslie, H.J.G.M. Crijns

^*Corresponding author for this work

Research output: Contribution to journal › (Systematic) Review article › peer-review

Abstract

Sarcoidosis is a relatively rare inflammatory condition which potentially carries high morbidity and substantial mortality. Due to the fact that it does not subject patients to ionizing radiation, has high temporal, spatial and contrast resolutions, cardiovascular magnetic resonance imaging (CMR) has become an important diagnostic and prognostic modality in the evaluation for cardiac involvement in this condition. This review provides relevant dinical and pathophysiological background on cardiac sarcoidosis, whilst detailing the role of CMR imaging in the diagnosis, and management of this condition. (C) 2020 The Author(s). Published by Elsevier Inc.

Original language	English
Pages (from-to)	271-307
Number of pages	37
Journal	Progress in Cardiovascular Diseases
Volume	63
Issue number	3
DOIs	https://doi.org/10.1016/j.pcad.2020.03.011
Publication status	Published - 1 May 2020

Keywords

cardiovascular magnetic resonance
corticosteroid-therapy
delayed enhancement
diagnosis
dilated cardiomyopathy
heart failure
hypertrophic cardiomyopathy
late gadolinium enhancement
myocardial inflammation
positron-emission-tomography
prognosis
prognostic value
risk stratification
sarcoidosis
term-follow-up
ventricular dysfunction
ventricular tachycardia
Prognosis
Cardiovascular magnetic resonance
Late gadolinium enhancement
PROGNOSTIC VALUE
Risk stratification
Diagnosis
Heart failure
Sarcoidosis
Ventricular tachycardia
DILATED CARDIOMYOPATHY
LATE GADOLINIUM ENHANCEMENT
POSITRON-EMISSION-TOMOGRAPHY
HYPERTROPHIC CARDIOMYOPATHY
DELAYED ENHANCEMENT
CORTICOSTEROID-THERAPY
TERM-FOLLOW-UP
MYOCARDIAL INFLAMMATION
VENTRICULAR DYSFUNCTION

Access to Document

10.1016/j.pcad.2020.03.011Licence: CC BY-NC-ND

Cite this

@article{3a9bd735df5d4979bedc78fe4fee3b31,

title = "Review: Contrast-enhanced magnetic resonance in the diagnosis and management of cardiac sarcoidosis",

abstract = "Sarcoidosis is a relatively rare inflammatory condition which potentially carries high morbidity and substantial mortality. Due to the fact that it does not subject patients to ionizing radiation, has high temporal, spatial and contrast resolutions, cardiovascular magnetic resonance imaging (CMR) has become an important diagnostic and prognostic modality in the evaluation for cardiac involvement in this condition. This review provides relevant dinical and pathophysiological background on cardiac sarcoidosis, whilst detailing the role of CMR imaging in the diagnosis, and management of this condition. (C) 2020 The Author(s). Published by Elsevier Inc.",

keywords = "cardiovascular magnetic resonance, corticosteroid-therapy, delayed enhancement, diagnosis, dilated cardiomyopathy, heart failure, hypertrophic cardiomyopathy, late gadolinium enhancement, myocardial inflammation, positron-emission-tomography, prognosis, prognostic value, risk stratification, sarcoidosis, term-follow-up, ventricular dysfunction, ventricular tachycardia, Prognosis, Cardiovascular magnetic resonance, Late gadolinium enhancement, PROGNOSTIC VALUE, Risk stratification, Diagnosis, Heart failure, Sarcoidosis, Ventricular tachycardia, DILATED CARDIOMYOPATHY, LATE GADOLINIUM ENHANCEMENT, POSITRON-EMISSION-TOMOGRAPHY, HYPERTROPHIC CARDIOMYOPATHY, DELAYED ENHANCEMENT, CORTICOSTEROID-THERAPY, TERM-FOLLOW-UP, MYOCARDIAL INFLAMMATION, VENTRICULAR DYSFUNCTION",

author = "J.P. Smedema and G. Ainslie and H.J.G.M. Crijns",

note = "Funding Information: We gratefully acknowledge Alfred Musekiwa's expert statistical support, as well as Geert-Jan Zonneveld, Michael Wyeth, and Stella van Schalkwijk's skill in drawing the figures. Publisher Copyright: {\textcopyright} 2020 The Author(s)",

year = "2020",

month = may,

day = "1",

doi = "10.1016/j.pcad.2020.03.011",

language = "English",

volume = "63",

pages = "271--307",

journal = "Progress in Cardiovascular Diseases",

issn = "0033-0620",

publisher = "W.B. Saunders Ltd",

number = "3",

}

TY - JOUR

T1 - Review: Contrast-enhanced magnetic resonance in the diagnosis and management of cardiac sarcoidosis

AU - Smedema, J.P.

AU - Ainslie, G.

AU - Crijns, H.J.G.M.

N1 - Funding Information: We gratefully acknowledge Alfred Musekiwa's expert statistical support, as well as Geert-Jan Zonneveld, Michael Wyeth, and Stella van Schalkwijk's skill in drawing the figures. Publisher Copyright: © 2020 The Author(s)

PY - 2020/5/1

Y1 - 2020/5/1

N2 - Sarcoidosis is a relatively rare inflammatory condition which potentially carries high morbidity and substantial mortality. Due to the fact that it does not subject patients to ionizing radiation, has high temporal, spatial and contrast resolutions, cardiovascular magnetic resonance imaging (CMR) has become an important diagnostic and prognostic modality in the evaluation for cardiac involvement in this condition. This review provides relevant dinical and pathophysiological background on cardiac sarcoidosis, whilst detailing the role of CMR imaging in the diagnosis, and management of this condition. (C) 2020 The Author(s). Published by Elsevier Inc.

AB - Sarcoidosis is a relatively rare inflammatory condition which potentially carries high morbidity and substantial mortality. Due to the fact that it does not subject patients to ionizing radiation, has high temporal, spatial and contrast resolutions, cardiovascular magnetic resonance imaging (CMR) has become an important diagnostic and prognostic modality in the evaluation for cardiac involvement in this condition. This review provides relevant dinical and pathophysiological background on cardiac sarcoidosis, whilst detailing the role of CMR imaging in the diagnosis, and management of this condition. (C) 2020 The Author(s). Published by Elsevier Inc.

KW - cardiovascular magnetic resonance

KW - corticosteroid-therapy

KW - delayed enhancement

KW - diagnosis

KW - dilated cardiomyopathy

KW - heart failure

KW - hypertrophic cardiomyopathy

KW - late gadolinium enhancement

KW - myocardial inflammation

KW - positron-emission-tomography

KW - prognosis

KW - prognostic value

KW - risk stratification

KW - sarcoidosis

KW - term-follow-up

KW - ventricular dysfunction

KW - ventricular tachycardia

KW - Prognosis

KW - Cardiovascular magnetic resonance

KW - Late gadolinium enhancement

KW - PROGNOSTIC VALUE

KW - Risk stratification

KW - Diagnosis

KW - Heart failure

KW - Sarcoidosis

KW - Ventricular tachycardia

KW - DILATED CARDIOMYOPATHY

KW - LATE GADOLINIUM ENHANCEMENT

KW - POSITRON-EMISSION-TOMOGRAPHY

KW - HYPERTROPHIC CARDIOMYOPATHY

KW - DELAYED ENHANCEMENT

KW - CORTICOSTEROID-THERAPY

KW - TERM-FOLLOW-UP

KW - MYOCARDIAL INFLAMMATION

KW - VENTRICULAR DYSFUNCTION

U2 - 10.1016/j.pcad.2020.03.011

DO - 10.1016/j.pcad.2020.03.011

M3 - (Systematic) Review article

C2 - 32330463

SN - 0033-0620

VL - 63

SP - 271

EP - 307

JO - Progress in Cardiovascular Diseases

JF - Progress in Cardiovascular Diseases

IS - 3

ER -